
Selecting Asthma Patients for 6-Month IL-5 Dosing: Fit and Safety
Most eligible patients stand to benefit from twice-yearly dosing, though candidate selection still matters, and clinical trial data reveal no new safety signals relative to more frequently dosed agents.
Episodes in this series

In "Selecting Asthma Patients for 6-Month IL-5 Dosing: Fit and Safety," the experts clarify who is best suited to extended-interval therapy and what the safety evidence shows.
Dr. Bernstein asks Dr. Wechsler how he decides which patients are appropriate for 6-month dosing. Dr. Wechsler emphasizes shared decision-making. The first step is choosing the class and mechanism: anti-IL-5, anti-IL-4 receptor, anti-TSLP, or anti-IgE. He calls this the fundamental question.
For most patients with type 2 inflammation, especially eosinophilic disease, no clinician would be faulted for choosing any of these strategies. Other factors then come into play. He considers asthma-specific and inflammation-specific features, patient-related factors, and comorbidities. For example, a patient with atopic dermatitis might receive a different biologic than one with chronic sinusitis.
Patient-related factors include whether dosing happens at home or in the office, and whether it occurs every 2, 4, or 8 weeks or every 6 months. These questions matter for busy patients, frequent travelers, and those who struggle to reach the office monthly.
He also identifies patients who may not be good candidates. Those who frequently miss appointments risk losing control if they fail to show for a twice-yearly dose. Considerations, he concludes, span disease, patient, and lifestyle.
Dr. Bernstein then asks Dr. Mosnaim about safety data for longer-acting, depot-style IL-5 inhibition. She served as a site principal investigator in the depemokimab clinical trials.
She reports that the side effect profile is well balanced. There were no concerning or increased safety signals with every-6-month dosing compared with more frequently administered anti-IL-5 therapies. She finds that very reassuring.
She notes there was no concern about anaphylaxis, which has been seen very rarely with some other biologics. Her practice manages more than 500 patients on biologics. Speaking only from personal experience, she has never seen anaphylaxis with an anti-IL-5 agent. Another panelist indicates a similar experience in his own practice.
The panel closes with "The Future of Severe Asthma Care: Precision Medicine and Beyond," as Dr. Chupp, Dr. Wechsler, and Dr. Mosnaim reflect on how far severe asthma care has come and what lies ahead.
Related to this article







